Lung Treatment with MSC Injection Therapy

TREATMENT OF COPD BY STEM CELLS

COPD can be described by a restriction of airflow into and out of lungs, which makes breathing difficult. It is a progressive lung disease that can range from mild to severe. Chronic bronchitis and emphysema are the two primary forms of COPD.

No successful cure is there for COPD, whereas treatment choices like stem cell therapy can prevent more damage and improve the patient’s quality of life.

Pilot research show that 82% of patients with COPD shows improvements in the quality of life when undergoing stem cell therapy. The level of improvements differs from patient to patient. There are also clinical trials on idiopathic pulmonary fibrosis and stem cell therapy. While the disease is far more dangerous, good clinical outcomes have been seen in patients that use stem cells.

In order to treat diseases, adult stem cells are added into the damaged tissues. This is done by intravenous infusion or also nebulization of the cells into the lungs. Usually a series of two or three treatments is done over a week or 10 days. Stem cell treatment has the ability to cure or treat the disease. But, still, stem cell therapy is not suitable enough to cure other chronic lung conditions other than COPD. Stem cell therapy is also helpful in treating patients of cystic fibrosis other than COPD. But these studies are at the pre-clinical stage and need more for implications to benefit patients in the future.

Different stem cells are used to stimulate tissue regeneration. But, most promising is juvenile umbilical cord, Passage One stem cells. There cells are collected form the umbilical cord of live healthy births. Then they are carefully extracted and selected for by stem cell scientists. The cells are allowed to grow only a very small amount, then stopped. This is referred to Passage One. So these cells are still very young and have not replicated many times. This means they are powerful and can regenerate damaged tissue.

One of the promising therapeutic approaches for several incurable and degenerative lung diseases is the use of induced pluripotent stem cells or iPS cells that are grown into Mesenchymal stem cells. But, only limited data is available regarding the effect of iPS MSCs in short and long term chronic respiratory diseases.

 

Mesenchymal Stem Cell for Chronic Obstructive Pulmonary Disease

Patients suffering from chronic obstructive pulmonary disease often show irreversible, the chronic airway inflammation. However, currently, there is no curative, and effective treatment is there to manage the COPD. Or to manage or cure the symptoms of the patients and improve the quality of life. In diverse degenerative lung disease stem cell-based treatment provides a successful therapeutic approach.

Acute respiratory distress, cystic fibrosis, bronchopulmonary dysplasia, emphysema there all respiratory conditions show successful preclinical and clinical studies using mesenchymal stem cells.

Different clinical trials have been performed by using different stem cells for COPD, these include bone marrow mononuclear cells (BMMCs), bone marrow-derived MSCs, adipose-derived MSCs, adipose-derived stem cells (ADSCs) and also human umbilical cord stem cells, passage one ( hUCSC). The results show that using umbilical cord MSCs for lung diseases are safe and improve the patient condition, whereas, large –scale study is still needed to prove the efficacy.

 

In summary, there has been some very good clinical results using adult stem cells for lung conditions over the past 15 years.  There are many published peer-reviewed clinical journal articles that prove beneficial outcomes using these adult stem cell technologies to treat lung conditions in Bangkok, Thailand. We have helped many COPD patients that have had the treatment and have tested before and after lung function tests in these patients over the past 13 years. This treatment is now available in Bangkok, Thailand. Please contact us at www.bangkokstemcells.com to to learn more about stem cell therapy for lung conditions.